Karyopharm Therapeutics Inc. (NASDAQ: KPTI) today reported a successful outcome from the Phase 2 portion of the SEAL study evaluating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Karyopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated LiposarcomaSeptember 20, 2017 7:00 AM